论文部分内容阅读
目的评价卡培他滨联合奥沙利铂治疗晚期胃癌的临床疗效及安全性。方法 41例患者均予以奥沙利铂130 mg·m-2+5%葡萄糖注射液500 m L,静脉点滴2 h,同时化疗第1天开始口服卡培他滨1000 mg·m-2,每日2次,连续服用14 d,21 d为1个化疗周期,共治疗4个周期。化疗4周期后进行临床疗效评价,不良反应评价每个化疗周期进行1次。结果 38例患者完成预定化疗周期,完全缓解3例(7.89%),部分缓解11例(28.95%),稳定14(36.84%),进展10例(26.32%),客观缓解率为36.84%,疾病控制率为73.68%。主要化疗相关不良反应为骨髓抑制和消化道反应。结论卡培他滨联合奥沙利铂治疗晚期胃癌的客观缓解率较高,且不良反应大多可以耐受。
Objective To evaluate the clinical efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer. Methods 41 patients were given oxaliplatin 130 mg · m-2 + 5% glucose injection 500 m L, intravenous drip 2 h, and the first day of chemotherapy started capecitabine 1000 mg · m-2, each Day 2, taking 14 consecutive days, 21 d for a chemotherapy cycle, a total of 4 cycles. After 4 cycles of chemotherapy clinical efficacy evaluation, adverse reactions were evaluated once every chemotherapy cycle. Results Thirty-eight patients completed the planned cycle of chemotherapy, complete remission was achieved in 3 cases (7.89%), partial remission in 11 cases (28.95%), stable in 14 cases (36.84%), progression in 10 cases (26.32%), objective remission rate was 36.84% The control rate is 73.68%. The main chemotherapy-related adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Capecitabine and oxaliplatin treatment of advanced gastric cancer objective response rate is high, and most of the adverse reactions can be tolerated.